Developer docs
API playgroundTry for free, no card

Search company profiles

Biosency

Full company profile

uuid0002kgm

Namestring
Biosency
Legal namestring
BIOSENCY, SAS
Websiteurl
biosency.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Biosency is a French medical device company founded in July 2017 by Marie Pirotais and Yann Le Guillou, headquartered in the Rennes metropolitan area. It develops Bora care®, an integrated remote monitoring and predictive medicine solution for patients with chronic respiratory insufficiency, principally Chronic Obstructive Pulmonary Disease (COPD). The system combines a CE MDR Class IIa-certified connected wristband (Bora band®) that captures SpO2, heart rate, respiratory rate, and skin temperature, with a Bora box data transmission accessory and the Bora connect® cloud platform, which visualizes vital signs, tracks intelligent alerts, and integrates with healthcare professional workflows via SDK/API. Its core differentiator is the proprietary BVS³ predictive algorithm, validated across 8 clinical trials and 14 international scientific publications to predict COPD exacerbations approximately 4.4 days in advance with 86% sensitivity and 9% false positives, supported by 6 patent families and over 500,000 days of accumulated monitoring data.

Biosency sells through a hybrid model combining direct sales to pulmonologists and respiratory specialists with channel partnerships — most notably ResMed (France, Maghreb, certain European countries, signed October 2022), Duomed France (exclusive domestic distribution, signed November 2025), and Inogen (oxygen-therapy patients, signed January 2026). Revenue streams include hardware sales of the Bora band®, subscription-based remote monitoring services via Bora connect®, and the Bora flow module, which is certified compliant with HAS and ANS requirements and eligible for reimbursement by French Health Insurance. Pricing is not publicly disclosed. The company has accumulated €21 million in total funding (€14M dilutive, €7M non-dilutive) since founding, with the most recent €7M round closed in November 2023 from existing investors including Go Capital. In June 2026, Biosency was acquired by Withings, a connected-health platform, marking a strategic exit that integrates its respiratory monitoring capability into a broader consumer and clinical health ecosystem.

Short descriptiontext

Biosency develops Bora care®, a CE MDR-certified remote monitoring and predictive medicine platform for COPD patients, combining a connected wristband, cloud software, and a proprietary BVS³ AI algorithm that predicts exacerbations 4.4 days in advance. It sells to pulmonologists and hospitals in France and Europe via direct sales and channel partners.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRennes, France
HQ citystring
Rennes
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote patient monitoring, COPD predictive medicine, connected medical devices, respiratory telehealth platform, wearable vital sign monitoring
Industry4 codes
PRIMARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
SECONDARYHLAFAEAF
Home Respiratory & Sleep Therapy Providers (DME-Integrated)
SECONDARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Commercial Physical & Biological Research8731
Product category
Remote Patient Monitoring
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Remote Monitoring Services
TypeSubscription Recurring
Description

Subscription-based remote patient monitoring services through Bora connect® platform, providing continuous vital sign monitoring and predictive alerts for COPD patients. Revenue derived from healthcare provider subscriptions for access to the platform and monitoring services.

biosency.com
2Bora band® Medical Device Sales
TypeHardware Sales
Description

Sale of Bora band® connected wristband - a Class IIa medical device for measuring and monitoring vital signs in patients with respiratory insufficiency. Device sold to healthcare providers and patients for home use.

biosency.com
3Bora flow Module
TypeSubscription Recurring
Description

Remote monitoring module for patients on respiratory assistance, certified compliant with HAS and ANS requirements, eligible for reimbursement by French Health Insurance.

biosency.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Bora care®
Description

Integrated home monitoring solution for COPD patients, combining remote monitoring and predictive medicine

biosency.com
+5 more records
Core offering1 text field

Biosency develops and commercializes Bora care®, an integrated remote patient monitoring and predictive medicine solution for COPD and chronic respiratory insufficiency patients. The offering combines the Bora band® connected wristband (Class IIa CE MDR certified medical device measuring SpO2, heart rate, respiratory rate, and skin temperature), the Bora connect® cloud platform for healthcare professionals, the Bora flow module for respiratory assistance monitoring, and the proprietary BVS³ predictive algorithm that anticipates COPD exacerbations approximately 4.4 days in advance. The solution is sold primarily to pulmonologists, hospitals, and respiratory care centers across Europe, with selective distribution partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • COPD exacerbations detected approximately 4.4 days before they occur
+3 more records
Product overview1 text field

Biosency offers Bora care®, an integrated remote monitoring and predictive medicine solution for COPD patients. The portfolio consists of Bora connect® cloud platform (for data visualization and alert management), Bora band® connected wristband (for vital signs collection), and Bora flow module (for respiratory assistance monitoring). Additional components include Bora box (data transmission device) and Bora partner (SDK/API integration option). The BVS³ AI algorithm provides predictive analytics to detect COPD exacerbations approximately 4.4 days before they occur. All components are CE MDR Class IIa certified.

Product and service4 records
1Bora care®
CategoryRemote Patient Monitoring Solution
Description

Integrated home monitoring solution combining the Bora band® wristband, Bora connect® cloud platform, and Bora flow module to deliver remote monitoring and predictive medicine for COPD and chronic respiratory insufficiency patients. The solution enables early detection of exacerbations via the BVS³ predictive score and is CE MDR Class IIa certified. It is sold to pulmonologists, hospitals, and respiratory care centers.

2Bora connect®
CategoryHealthcare Cloud Platform
Description

Cloud-based platform available via web browser and mobile application for healthcare professionals. Provides visualization of vital signs and respiratory assistance machine data, customizable parameters, intelligent alert tracking, and SDK/API for third-party integration. Targets pulmonologists, respiratory therapists, and care teams managing chronic respiratory patients.

3Bora band®
CategoryMedical Wearable Device
Description

Connected wristband that collects vital signs (SpO2, heart rate, respiratory rate, skin temperature) in real life for remote monitoring of patients with respiratory insufficiency. Lightweight, waterproof (IP64), with up to 5 days battery life and single-button operation. CE MDR Class IIa certified, produced exclusively in France. Sold to healthcare providers and prescribed for home use by COPD and chronic respiratory patients.

4Bora flow
CategoryRemote Monitoring Module
Description

Remote monitoring module for patients on respiratory assistance, providing a clinical dashboard with customizable alerts for healthcare professionals. Enables compliance tracking and health status change detection for patients using respiratory assistance devices. Certified compliant with HAS and ANS requirements and eligible for reimbursement by French Health Insurance.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Biosency announced it is joining Withings, a leading player in connected health. This acquisition marks a significant step in Biosency's development, reflecting shared ambition to accelerate innovation in remote respiratory monitoring, strengthen impact of remote monitoring solutions, and advance preventive, continuous, and accessible healthcare.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Strategic collaboration with Inogen, world leader in portable oxygen concentrators, to create the first remote monitoring solution with automated data transmission for patients on oxygen therapy. Enables remote monitoring of patients on oxygen therapy through a unique medical platform designed with and for healthcare professionals.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-01
Description

Exclusive partnership with Duomed France, a major medical device distributor in France, to accelerate deployment of Bora care® and facilitate access to the solution for healthcare professionals. Aims to enhance monitoring of patients with respiratory failure, particularly COPD patients.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-10-01
Description

Strategic partnership with ResMed, world leader in innovative solutions for treatment of respiratory disorders. ResMed distributes Bora care® remote monitoring solution to healthcare professionals in France, Maghreb, and certain European countries for patients with respiratory failure.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Remote patient monitoring platform supporting multiple chronic conditions including COPD, with mobile kits and integration into health system workflows. Comparable RPM platform play.

TypeDirect peer
Description

Direct competitor in respiratory remote monitoring focused on asthma and COPD medication adherence and exacerbation prediction. Acquired by ResMed in 2019, making it the closest direct peer in COPD/asthma RPM.

TypeEmerging player
Description

Telehealth and remote examination device company with overlapping RPM and chronic care management capabilities, including respiratory assessment, serving providers and payors.

TypeBroad incumbent
Description

Global leader in sleep and respiratory care devices, including CPAP and ventilation equipment. ResMed is both a strategic partner (distributes Bora care®) and a broad incumbent competing in respiratory patient management, having acquired Propeller Health for asthma/COPD RPM.

TypeBroad incumbent
Description

Diversified medtech incumbent with a large respiratory and sleep portfolio (ventilators, CPAP) plus connected care/telehealth offerings. Competes in the broader hospital-to-home respiratory care continuum.

6HGE Health
TypeDirect peer
Description

Digital health company offering remote monitoring specifically for COPD patients, with predictive algorithms to reduce hospitalizations. Closely aligned niche and use case as Biosency's Bora care®.

TypeDirect peer
Description

RPM platform offering cellular-connected vital sign monitoring for chronic conditions including COPD, sold to health systems and home health agencies in North America and Europe.

TypeDirect peer
Description

Digital health company focused on respiratory remote monitoring, particularly asthma and COPD medication adherence sensors and patient management platforms. Comparable niche in connected respiratory drug delivery.

TypeEmerging player
Description

Smaller emerging player building connected respiratory devices and adherence/symptom monitoring tools. Competes in adjacent connected inhaler and respiratory monitoring use cases.

TypeOthers
Description

Leading connected health device maker (smart scales, watches, sleep mats) and now Biosency's parent company. Comparable as a connected health platform player and ecosystem participant in RPM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biosency

Remote Patient Monitoringbiosency.com

Biosency develops Bora care®, a CE MDR-certified remote monitoring and predictive medicine platform for COPD patients, combining a connected wristband, cloud software, and a proprietary BVS³ AI algorithm that predicts exacerbations 4.4 days in advance. It sells to pulmonologists and hospitals in France and Europe via direct sales and channel partners.

What Biosency does

Biosency is a French medical device company founded in July 2017 by Marie Pirotais and Yann Le Guillou, headquartered in the Rennes metropolitan area. It develops Bora care®, an integrated remote monitoring and predictive medicine solution for patients with chronic respiratory insufficiency, principally Chronic Obstructive Pulmonary Disease (COPD). The system combines a CE MDR Class IIa-certified connected wristband (Bora band®) that captures SpO2, heart rate, respiratory rate, and skin temperature, with a Bora box data transmission accessory and the Bora connect® cloud platform, which visualizes vital signs, tracks intelligent alerts, and integrates with healthcare professional workflows via SDK/API. Its core differentiator is the proprietary BVS³ predictive algorithm, validated across 8 clinical trials and 14 international scientific publications to predict COPD exacerbations approximately 4.4 days in advance with 86% sensitivity and 9% false positives, supported by 6 patent families and over 500,000 days of accumulated monitoring data.

Biosency sells through a hybrid model combining direct sales to pulmonologists and respiratory specialists with channel partnerships — most notably ResMed (France, Maghreb, certain European countries, signed October 2022), Duomed France (exclusive domestic distribution, signed November 2025), and Inogen (oxygen-therapy patients, signed January 2026). Revenue streams include hardware sales of the Bora band®, subscription-based remote monitoring services via Bora connect®, and the Bora flow module, which is certified compliant with HAS and ANS requirements and eligible for reimbursement by French Health Insurance. Pricing is not publicly disclosed. The company has accumulated €21 million in total funding (€14M dilutive, €7M non-dilutive) since founding, with the most recent €7M round closed in November 2023 from existing investors including Go Capital. In June 2026, Biosency was acquired by Withings, a connected-health platform, marking a strategic exit that integrates its respiratory monitoring capability into a broader consumer and clinical health ecosystem.

Biosency firmographics

Firmographics
Name
Biosency
Legal name
BIOSENCY, SAS
Website
https://biosency.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Biosency develops Bora care®, a CE MDR-certified remote monitoring and predictive medicine platform for COPD patients, combining a connected wristband, cloud software, and a proprietary BVS³ AI algorithm that predicts exacerbations 4.4 days in advance. It sells to pulmonologists and hospitals in France and Europe via direct sales and channel partners.
Ownership category
akta.pro rank

Biosency industry classification

Industry
Product category
Remote Patient Monitoring
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
SECONDARYHLAFAEAF
Home Respiratory & Sleep Therapy Providers (DME-Integrated)
SECONDARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Remote patient monitoring
  • COPD predictive medicine
  • Connected medical devices
  • Respiratory telehealth platform
  • Wearable vital sign monitoring

Where Biosency is headquartered

Location

Headquarters

HQ city
Rennes
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Biosency business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Remote Monitoring Services: Subscription-based remote patient monitoring services through Bora connect® platform, providing continuous vital sign monitoring and predictive alerts for COPD patients. Revenue derived from healthcare provider subscriptions for access to the platform and monitoring services.
  2. Bora band® Medical Device Sales: Sale of Bora band® connected wristband - a Class IIa medical device for measuring and monitoring vital signs in patients with respiratory insufficiency. Device sold to healthcare providers and patients for home use.
  3. Bora flow Module: Remote monitoring module for patients on respiratory assistance, certified compliant with HAS and ANS requirements, eligible for reimbursement by French Health Insurance.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Biosency product offering

Product offering

Core offering

Biosency develops and commercializes Bora care®, an integrated remote patient monitoring and predictive medicine solution for COPD and chronic respiratory insufficiency patients. The offering combines the Bora band® connected wristband (Class IIa CE MDR certified medical device measuring SpO2, heart rate, respiratory rate, and skin temperature), the Bora connect® cloud platform for healthcare professionals, the Bora flow module for respiratory assistance monitoring, and the proprietary BVS³ predictive algorithm that anticipates COPD exacerbations approximately 4.4 days in advance. The solution is sold primarily to pulmonologists, hospitals, and respiratory care centers across Europe, with selective distribution partnerships.

Product overview

Biosency offers Bora care®, an integrated remote monitoring and predictive medicine solution for COPD patients. The portfolio consists of Bora connect® cloud platform (for data visualization and alert management), Bora band® connected wristband (for vital signs collection), and Bora flow module (for respiratory assistance monitoring). Additional components include Bora box (data transmission device) and Bora partner (SDK/API integration option). The BVS³ AI algorithm provides predictive analytics to detect COPD exacerbations approximately 4.4 days before they occur. All components are CE MDR Class IIa certified.

Differentiator

Problem solved

Functional benefit

Brands

  • Bora care®: Integrated home monitoring solution for COPD patients, combining remote monitoring and predictive medicine
  • Bora connect®
  • Bora flow
  • Bora band®
  • Bora box
  • BVS3®

Products and services

  • Bora care® Integrated home monitoring solution combining the Bora band® wristband, Bora connect® cloud platform, and Bora flow module to deliver remote monitoring and predictive medicine for COPD and chronic respiratory insufficiency patients. The solution enables early detection of exacerbations via the BVS³ predictive score and is CE MDR Class IIa certified. It is sold to pulmonologists, hospitals, and respiratory care centers.
  • Bora connect® Cloud-based platform available via web browser and mobile application for healthcare professionals. Provides visualization of vital signs and respiratory assistance machine data, customizable parameters, intelligent alert tracking, and SDK/API for third-party integration. Targets pulmonologists, respiratory therapists, and care teams managing chronic respiratory patients.
  • Bora band® Connected wristband that collects vital signs (SpO2, heart rate, respiratory rate, skin temperature) in real life for remote monitoring of patients with respiratory insufficiency. Lightweight, waterproof (IP64), with up to 5 days battery life and single-button operation. CE MDR Class IIa certified, produced exclusively in France. Sold to healthcare providers and prescribed for home use by COPD and chronic respiratory patients.
  • Bora flow Remote monitoring module for patients on respiratory assistance, providing a clinical dashboard with customizable alerts for healthcare professionals. Enables compliance tracking and health status change detection for patients using respiratory assistance devices. Certified compliant with HAS and ANS requirements and eligible for reimbursement by French Health Insurance.

Quantifiable outcome

  • COPD exacerbations detected approximately 4.4 days before they occur
  • +3 more outcomes

Companies that use Biosency

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Biosency technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Biosency partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • WithingsflagshipStrategic or Co-development Partner · 1 June 2026Biosency announced it is joining Withings, a leading player in connected health. This acquisition marks a significant step in Biosency's development, reflecting shared ambition to accelerate innovation in remote respiratory monitoring, strengthen impact of remote monitoring solutions, and advance preventive, continuous, and accessible healthcare.
  • InogencoreStrategic or Co-development Partner · 1 January 2026Strategic collaboration with Inogen, world leader in portable oxygen concentrators, to create the first remote monitoring solution with automated data transmission for patients on oxygen therapy. Enables remote monitoring of patients on oxygen therapy through a unique medical platform designed with and for healthcare professionals.
  • Duomed FrancecoreChannel Partner/ Reseller/ Distributor · 1 November 2025Exclusive partnership with Duomed France, a major medical device distributor in France, to accelerate deployment of Bora care® and facilitate access to the solution for healthcare professionals. Aims to enhance monitoring of patients with respiratory failure, particularly COPD patients.
  • ResMedcoreChannel Partner/ Reseller/ Distributor · 1 October 2022Strategic partnership with ResMed, world leader in innovative solutions for treatment of respiratory disorders. ResMed distributes Bora care® remote monitoring solution to healthcare professionals in France, Maghreb, and certain European countries for patients with respiratory failure.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Biosency competitors and assessment

Company assessment

Direct peers

  • Vivify Health: Remote patient monitoring platform supporting multiple chronic conditions including COPD, with mobile kits and integration into health system workflows. Comparable RPM platform play.
  • Propeller Health: Direct competitor in respiratory remote monitoring focused on asthma and COPD medication adherence and exacerbation prediction. Acquired by ResMed in 2019, making it the closest direct peer in COPD/asthma RPM.
  • HGE Health: Digital health company offering remote monitoring specifically for COPD patients, with predictive algorithms to reduce hospitalizations. Closely aligned niche and use case as Biosency's Bora care®.
  • CareSimple: RPM platform offering cellular-connected vital sign monitoring for chronic conditions including COPD, sold to health systems and home health agencies in North America and Europe.
  • Adherium: Digital health company focused on respiratory remote monitoring, particularly asthma and COPD medication adherence sensors and patient management platforms. Comparable niche in connected respiratory drug delivery.

Emerging players

  • Tytocare: Telehealth and remote examination device company with overlapping RPM and chronic care management capabilities, including respiratory assessment, serving providers and payors.
  • Smart Respiratory Products: Smaller emerging player building connected respiratory devices and adherence/symptom monitoring tools. Competes in adjacent connected inhaler and respiratory monitoring use cases.

Broad incumbents

  • ResMed: Global leader in sleep and respiratory care devices, including CPAP and ventilation equipment. ResMed is both a strategic partner (distributes Bora care®) and a broad incumbent competing in respiratory patient management, having acquired Propeller Health for asthma/COPD RPM.
  • Philips: Diversified medtech incumbent with a large respiratory and sleep portfolio (ventilators, CPAP) plus connected care/telehealth offerings. Competes in the broader hospital-to-home respiratory care continuum.

Others

  • Withings: Leading connected health device maker (smart scales, watches, sleep mats) and now Biosency's parent company. Comparable as a connected health platform player and ecosystem participant in RPM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Biosency social profiles

Digital presence

Biosency compliance and trust

Trust signal

Compliance6 records

Biosency financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biosency leadership team

Management profile

Number of profiles

Profiles3 records

Biosency funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biosency M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosency

What does Biosency do?

Biosency develops and commercializes Bora care®, an integrated remote patient monitoring and predictive medicine solution for COPD and chronic respiratory insufficiency patients. The offering combines the Bora band® connected wristband (Class IIa CE MDR certified medical device measuring SpO2, heart rate, respiratory rate, and skin temperature), the Bora connect® cloud platform for healthcare professionals, the Bora flow module for respiratory assistance monitoring, and the proprietary BVS³ predictive algorithm that anticipates COPD exacerbations approximately 4.4 days in advance. The solution is sold primarily to pulmonologists, hospitals, and respiratory care centers across Europe, with selective distribution partnerships.

Is Biosency a public or private company?

Biosency is a private company. It is classified as corporate owned and is currently acquired.

When was Biosency founded?

Biosency was founded in 2017. It employs 11 to 50 people.

Where is Biosency based?

Biosency is headquartered in Rennes, France, in the Europe region.

How does Biosency make money?

Three revenue lines are on record. Remote Monitoring Services are the primary driver. The others are bora band® Medical Device Sales and bora flow Module.

Who are Biosency's main competitors?

Direct peers on record are Vivify Health, Propeller Health, HGE Health, CareSimple and Adherium. Emerging players are Tytocare and Smart Respiratory Products. Broad incumbents are ResMed and Philips. Withings is listed as an others.

Does Biosency have an API?

Yes. Bora connect® platform interfaces with other platforms via SDK/API. The Bora partner option enables the Bora band® to be integrated into third-party remote monitoring platforms, with data from the wristband sent via SDK/API. No public documentation URL, pricing, or developer portal specified.

What industry is Biosency in?

Biosency's product category is Remote Patient Monitoring. Its primary akta.pro industry code is HLAKANAE, COPD & Chronic Bronchitis Management, with a secondary code of HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 5417 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HLTHWithings Acquires Biosency to Expand Respiratory Remote Monitoring CapabilitiesWithings acquired Biosency, a French developer of remote monitoring for respiratory insufficiency, to enter respiratory remote monitoring. Biosency's platform detects COPD exacerbations early, and its team will join Withings from Rennes. The deal expands Withings' connected care portfolio beyond cardiometabolic health.Health Tech WorldWithings acquires Biosency and enters respiratory monitoring spaceWithings acquired Biosency, a French company that develops remote monitoring systems for patients with respiratory insufficiency. The system includes a medically certified algorithm to detect early signs of COPD exacerbations. Biosency will join Withings to commercialize and expand its system.MaddynessWithings reprend la medtech rennaise BiosencyWithings, a French connected health company based in Issy-les-Moulineaux, has acquired Biosency, a Rennes-based medtech startup that had been placed in judicial receivership. Biosency, founded in 2017, specialized in monitoring patients with respiratory insufficiency and had raised €7 million in 2023 but failed to close a subsequent fundraising round. The acquisition enables Withings to expand into respiratory telemedicine, with Biosency's team continuing development from Rennes under Withings' ownership.Real DealsLa start-up Biosency lève 7 M€Biosency, a startup specializing in remote monitoring devices for chronic respiratory diseases, announced a funding round of €7 million from historical investors including Go Capital and private partners. This latest raise brings the company's total capital raised since its 2017 founding to €21 million. The announcement highlights Biosency's status as a laureate of a specific medical benefit evaluation call for projects.PR NewswireBiosency detects early COPD exacerbations thanks to Bora care®, a predictive digital medical deviceFrench MedTech company Biosency presented clinical results at the ATS 2023 conference in Washington D.C. demonstrating that its BVS3 technology can predict acute COPD exacerbations on average 3 days before hospitalization with 86% accuracy and only 9% false positives, compared to 20% for equivalent devices. The study monitored 85 COPD patients over six months using the BORA Care® connected device, which measures oxygen saturation, heart rate, and respiratory rate in real time. The company plans to make the BVS3 technology commercially available to healthcare professionals from 2024 and is pursuing regulatory approval for reimbursement through an advance payment scheme.